Sun Pharma shares in focus as management reiterates FY27 guidance; Analysts see up to 31% upside

Sun Pharma's management said the company witnessed slowdown in the drug Illumya's sales in the second quarter. The company has identified factors that led to the slowdown and will focus on execution to revive growth, the management added.